Technical Analysis for NERV - Minerva Neurosciences, Inc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| NR7-2 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Calm After Storm | Range Contraction | -0.86% | |
| NR7 | Range Contraction | -0.86% | |
| Narrow Range Bar | Range Contraction | -0.86% | |
| Inside Day | Range Contraction | -0.86% | |
| Fell Below 20 DMA | Bearish | 3.70% | |
| Calm After Storm | Range Contraction | 3.70% |
| Alert | Time |
|---|---|
| Possible NR7 | about 6 hours ago |
| Rose Above Previous Day's High | about 8 hours ago |
| Up 1% | about 8 hours ago |
| 60 Minute Opening Range Breakout | about 8 hours ago |
| Down 1% | about 10 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 07/30/2024
Minerva Neurosciences, Inc Description
Minerva Neurosciences, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidates that have completed Phase IIa trials comprise MIN-101, an antagonist on 5-HT2A and sigma2 receptors for the treatment of patients with schizophrenia; and MIN-117, an antagonist on the 5-HT1A receptor, and inhibitor of serotonin and dopamine reuptake for the treatment of major depressive disorder. It is also developing MIN-202, a selective orexin 2 receptor antagonist that is in Phase Ib trials for the treatment of primary and secondary insomnia; and MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein, which is in investigational new drug-enabling studies for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of MIN-202. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences Inc. in 2013. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Neuroscience Parkinson's Disease Psychoactive Drugs Schizophrenia Major Depressive Disorder Depressive Disorder Treatment Of Parkinson's Disease Neurochemistry Antidepressants Ketones Treatment Of Major Depressive Disorder Insomnia Central Nervous System Disease Dopamine Investigational New Drug Treatment Of Central Nervous System Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.49 |
| 52 Week Low | 2.26 |
| Average Volume | 38,714 |
| 200-Day Moving Average | 5.00 |
| 50-Day Moving Average | 2.77 |
| 20-Day Moving Average | 3.25 |
| 10-Day Moving Average | 3.30 |
| Average True Range | 0.23 |
| RSI (14) | 53.27 |
| ADX | 25.48 |
| +DI | 17.51 |
| -DI | 21.22 |
| Chandelier Exit (Long, 3 ATRs) | 2.99 |
| Chandelier Exit (Short, 3 ATRs) | 2.96 |
| Upper Bollinger Bands | 3.61 |
| Lower Bollinger Band | 2.88 |
| Percent B (%b) | 0.39 |
| BandWidth | 22.28 |
| MACD Line | 0.12 |
| MACD Signal Line | 0.16 |
| MACD Histogram | -0.0466 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.30 | ||||
| Resistance 3 (R3) | 3.31 | 3.27 | 3.28 | ||
| Resistance 2 (R2) | 3.27 | 3.23 | 3.26 | 3.27 | |
| Resistance 1 (R1) | 3.22 | 3.21 | 3.20 | 3.21 | 3.26 |
| Pivot Point | 3.18 | 3.18 | 3.17 | 3.17 | 3.18 |
| Support 1 (S1) | 3.13 | 3.14 | 3.11 | 3.12 | 3.07 |
| Support 2 (S2) | 3.09 | 3.12 | 3.08 | 3.06 | |
| Support 3 (S3) | 3.04 | 3.09 | 3.05 | ||
| Support 4 (S4) | 3.03 |
